NasdaqGS - Nasdaq Real Time Price USD

Day One Biopharmaceuticals, Inc. (DAWN)

6.48

+0.23

+(3.68%)

At close: 4:00:00 PM EDT

6.46

-0.02

(-0.31%)

After hours: 4:24:49 PM EDT

Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now?

We recently published a list of 10 Best Low Priced Biotech Stocks to Buy Now. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against other best low priced biotech stocks to buy now. Is Now the Time to Buy Biotech Stocks? On May 8, Michael […]

Insider Monkey 6 days ago

DAWN
+3.68%
Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030?

We recently published a list of 10 Low Risk High Reward Stocks Set to Triple by 2030. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against other low risk high reward stocks set to triple by 2030. The market is getting tough these days with […]

Insider Monkey 10 days ago

DAWN
+3.68%
Q1 2025 Day One Biopharmaceuticals Inc Earnings Call

Q1 2025 Day One Biopharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 12 days ago

DAWN
+3.68%
Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Day One Biopharmaceuticals Inc (DAWN) reports robust financial performance with significant script growth and a solid cash position, while navigating market challenges.

GuruFocus.com 12 days ago

DAWN
+3.68%
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of 23.91% and 4.90%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 12 days ago

DAWN
+3.68%
Day One Reports First Quarter 2025 Financial Results and Corporate Progress

OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing

GlobeNewswire 13 days ago

DAWN
+3.68%
Q1 2025 American International Group Inc Earnings Call

Q1 2025 American International Group Inc Earnings Call

Thomson Reuters StreetEvents 16 days ago

AIG

DAWN
+3.68%
Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be acce

GlobeNewswire 27 days ago

DAWN
+3.68%
Exploring US High Growth Tech Stocks This April 2025

Amidst a backdrop of heightened market volatility driven by recent tariff implementations and retaliatory measures, the U.S. stock market has experienced significant fluctuations, with key indices like the Dow Jones and S&P 500 showing mixed performances while the tech-heavy Nasdaq Composite has seen notable gains. In this environment, identifying high-growth tech stocks requires careful consideration of their resilience to economic pressures and their potential for innovation-driven...

Simply Wall St. last month

PGEN

API

DAWN
+3.68%
Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple

We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on […]

Insider Monkey last month

DAWN
+3.68%
High Growth Tech Stocks In The US With Promising Potential

Over the last 7 days, the United States market has experienced a 1.7% drop, yet it remains up by 12% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in an evolving market landscape.

Simply Wall St. 2 months ago

ARDX

DAWN
+3.68%

BSY
Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

We came across a bullish thesis on Day One Biopharmaceuticals, Inc. (DAWN) on Twitter by Pharmdca. In this article, we will summarize the bulls’ thesis on DAWN. Day One Biopharmaceuticals, Inc. (DAWN)’s share was trading at $8.60 as of March 4th. DAWN is an undervalued commercial-stage oncology company with a long-term target in the mid-$30s, driven by […]

Insider Monkey 2 months ago

DAWN
+3.68%
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

Zacks 2 months ago

DAWN
+3.68%
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -97.14% and 7.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

DAWN
+3.68%
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted

GlobeNewswire 2 months ago

DAWN
+3.68%
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.

Zacks 2 months ago

INSM

DAWN
+3.68%
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 3 months ago

DAWN
+3.68%
New Strong Buy Stocks for February 13th

SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.

Zacks 3 months ago

SYF-PB

DAWN
+3.68%
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the fourth quarter and full-year 2024. Live audio of the

GlobeNewswire 3 months ago

DAWN
+3.68%
Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?

We recently compiled a list of the Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks. In this article, we are going to take a look at where Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one […]

Insider Monkey 3 months ago

DAWN
+3.68%

Performance Overview

Return	DAWN	S&P 500 (^GSPC)
YTD	-48.86%	+1.39%
1-Year	-59.93%	+12.45%
3-Year	-5.81%	+52.88%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Day One Biopharmaceuticals, Inc. (DAWN)

Is Day One Biopharmaceuticals, Inc. (DAWN) the Best Low Priced Biotech Stock to Buy Now?

Is Day One Biopharmaceuticals, Inc. (DAWN) the Low Risk High Reward Stock Set to Triple by 2030?

Q1 2025 Day One Biopharmaceuticals Inc Earnings Call

Day One Biopharmaceuticals Inc (DAWN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ...

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

Q1 2025 American International Group Inc Earnings Call

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Exploring US High Growth Tech Stocks This April 2025

Day One Biopharmaceuticals, Inc. (DAWN): Among Stocks Under $10 that Will Triple

High Growth Tech Stocks In The US With Promising Potential

Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?

New Strong Buy Stocks for February 13th

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Why Is Andreas Halvorsen Bullish On Day One Biopharmaceuticals, Inc. (DAWN) Now?

Performance Overview